|
Investigator's Choice of Therapy Clinical Trials
2 actively recruiting trials across 1 location
▲ +1 trial since August 2026
Also known as: Fruquintinib or Trifluridine and Tipiracil Hydrochloride or Regorafenib
Pipeline
Phase 3: 2
Top Sponsors
- Zai Lab (Shanghai) Co., Ltd.1
- Innovent Biologics (Suzhou) Co. Ltd.1
Indications
- Cancer2
- Colorectal Cancer1
- Small Cell Lung Cancer1
- Lung Cancer1
Other1 trial
La Jolla, California1 trial
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
University of California San Diego
Phase 3
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.